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Abstract
Background: C4-2 prostate cancer (CaP) cells grown in mouse tibiae cause a mixed osteoblastic/
osteolytic response with increases in osteoclast numbers and bone resorption. Administration of
osteoprotegerin (OPG) blocks these increases, indicating the critical role of RANKL in osteolysis
in this model. The objective of our study was to investigate whether RANKL expressed by tumor
cells (human origin) directly stimulates osteolysis associated with the growth of these cells in bone
or whether the increased osteolysis is caused by RANKL expressed by the host environment cells
(murine origin). The relative contribution of tumor-vs. host-derived RANKL has been difficult to
establish, even with human xenografts, because murine and human RANKL are both capable of
stimulating osteolysis in mice, and the RANKL inhibitors used to date (OPG and RANK-Fc) inhibit
human and murine RANKL.
Methods: To address this question we used a neutralizing, antibody (huRANKL MAb), which
specifically neutralizes the biological activities of human RANKL and thereby the contribution of
C4-2 derived RANKL in this tibial injection model of experimental bone metastases.
Results: Administration of huRANKL MAb did not inhibit the osteolytic response of the bone to
these cells, or affect the establishment and growth of the C4-2 tumors in this environment.
Conclusion: In conclusion, our results suggest that in this model, murine RANKL and not the
tumor-derived human RANKL is the mediator of the osteolytic reaction associated with C4-2
growth in bone. We hypothesize that C4-2 cells express other factor/s inducing host production
of RANKL, thereby driving tumor-associated osteolysis.
Background
Prostate cancer (CaP) predominantly metastasizes to the
bone, and bone metastases are the main cause of morbid-
ity. While CaP metastases are usually osteoblastic in
nature [1-3], there is an osteolytic component to the dis-
ease [4,5] which is manifested by increases in osteolytic
markers in the serum and urine of patients with advanced
CaP [6-8]. Increased bone resorption is also a prognostic
factor for skeletal-related events in metastatic CaP [9].
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However, how CaP cells induce an increased osteolytic
reaction is not fully understood.
The RANKL/RANK/OPG system is critical in regulating
osteoclastogenesis, and therefore is involved in bone
remodeling (reviewed in [10]). Osteoclastogenesis is reg-
ulated by the interaction between receptor activator of
NFκB ligand (RANKL) and its receptor RANK. RANK is
expressed on bone marrow-derived osteoclast progeni-
tors, and its activation upon binding of RANKL is required
for differentiation of these progenitors into osteoclasts
[10,11]. Osteoprotegerin (OPG), a soluble decoy receptor
for RANKL inhibits osteoclastogenesis by interfering with
RANKL-RANK interactions [12]. Recently, RANKL has
been identified as a potential mediator of cancer-induced
bone destruction in humans [13].
Our interest in the role of RANKL/RANK/OPG signaling
in deregulation of bone remodeling-associated CaP bone
metastases originally led us to examine whether CaP cells
in the bone environment expressed these factors. We have
shown that normal prostate and primary CaP express
RANKL and OPG, and the levels of RANKL and OPG are
increased in CaP bone metastases vs.  those in primary
tumors and soft-tissue metastases [14]. CaP cell lines also
express RANK and RANKL [14-16], and RANKL was
reported to be instrumental in induction of osteoclas-
togenesis by CaP cells in vitro [16]. Soluble RANKL
released from CaP cells by MMP-7 was shown to play a
role in establishment of CaP bone metastases and osteol-
ysis associated with CaP bone lesions [17]. These data
constitute additional evidence of a role for RANK/RANKL
signaling in CaP bone metastases.
Results of preclinical studies have shown that inhibition
of RANK/RANKL signaling decreases tumor growth and/
or establishment and prevented osteolysis in CaP [16,18-
22] and other tumor types [23-25] in the bone environ-
ment. While these data are promising with regard to treat-
ment of advanced CaP, acquiring additional
understanding of the mechanisms of induction of osteo-
clastogenesis associated with prostate tumors in the bone
is a critical step to enable further advances in this area.
Cancer cells may cause osteolysis directly by expression of
RANKL or indirectly by inducing host production of
RANKL. The relative contribution of tumor-versus host-
derived RANKL has been difficult to establish, even with
human xenograft models, because murine and human
RANKL both cause osteolysis in mice. Furthermore, the
RANKL inhibitors used to date (OPG and RANK-Fc)
[16,18,20,22] or soluble RANK [19] inhibit both human
and murine RANKL.
The purpose of this study was to determine whether
RANKL expressed by C4-2 CaP cells is directly involved in
stimulation of osteoclastogenesis associated with the
growth of these cells in the bone environment. We have
used a model of experimental CaP bone metastases con-
sisting of direct injection of human C4-2 cells into mouse
tibiae and huRANKL MAb, an anti-human RANKL neu-
tralizing antibody to address this question. The use of
huRANKL MAb, has enabled us to separate the effect of
bone (murine) and tumor (human) RANKL. Our results
indicate that the human RANKL expressed by C4-2 cells
exerted little or no effect in this system and that RANKL
expressed by the host cells within the bone environment
is responsible for the stimulation of osteolysis. This
implies that CaP cells express factor/s other than RANKL
in this murine bone xenograft model that (a) stimulates
host cells to produce RANKL and/or (b) directly stimu-
lates osteoclastogenesis.
Methods
Tissue culture
C4-2 prostate cancer cells, a subline of LNCaP cells, were
purchased from Urocor, Inc. (Oklahoma City, OK) and
maintained under standard tissue culture conditions in
RPMI 1640 (Invitrogen Corp. Carlsbad, CA) supple-
mented with 10% fetal bovine serum (FBS) (Atlanta Bio-
logicals, Atlanta, GA).
Effects of OPG-Fc and huRANKL MAb on huRANKL-
induced Ca2+ release in mice
All animal procedures were performed in compliance
with the University of Washington and Amgen Institu-
tional Animal Care and Use Committees and NIH guide-
lines. Initially to characterize the specificity of the
huRANKL MAb to bind to human RANKL young male
BDF1 mice (4–5 weeks old, n = 5 per group) were injected
subcutaneously with 1, 3, or 10 mg/kg huRANKL MAb
(AMG 161, Amgen, Inc., Thousand Oaks, CA), 3 mg/kg
OPG-Fc (Amgen, Inc.), or PBS. Animals were then chal-
lenged twice daily (by subcutaneous injection morning
and evening) with either human RANKL (0.5 mg/kg,
Amgen, Inc.) or PBS for 6 days. Blood was collected 3
hours after each morning challenge. Blood Ca2+ was meas-
ured using a Ca2+/pH analyzer (Model 634, Chiron Diag-
nostics, Halstead, UK).
Effects of OPG-Fc and huRANKL MAb on systemic TRACP-
5b levels in mice
12-week-old female BALB/c mice (n = 5 per group) were
injected with a single subcutaneous injection of PBS,
OPG-Fc (10 mg/kg), or huRANKL MAb (10 mg/kg).
TRACP-5b activity in serum samples collected one hour
before (baseline) and 72 h after the treatment was meas-
ured using the mouse TRAP™ Assay (SBA Sciences, Turku,
Finland).BMC Cancer 2007, 7:148 http://www.biomedcentral.com/1471-2407/7/148
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Effect of huRANKL MAb on experimental CaP bone 
metastases
Once the neutralizing activity and specificity of the
huRANKL MAb in vivo were determined, we set up to
investigate the effects of inhibition of human RANKL on
osteolysis associated with C4-2 growth in the murine
bone. These experiments require use of SCID male mice.
We are unaware of any data indicating that bone remode-
ling would be different between wild-type and SCID mice.
Four-to six-week-old male SCID mice were injected with
approximately 1 × 105 C4-2 cells in 10 μL into the tibiae
as described previously [26,27]. Three groups of 10 ani-
mals each were used: 1) a control group, subcutaneous
injection of PBS twice a week; 2) a prevention group, sub-
cutaneous injection of huRANKL MAb (5 mg/kg) twice a
week, starting at time of tumor-cell injection; and 3) a
treatment group, subcutaneous injection of PBS twice a
week until week 3, and then injections of huRANKL MAb
(5 mg/kg) twice a week until sacrifice. Blood samples were
drawn from animals weekly for determination of serum
prostate specific antigen (PSA) levels starting at week 3
after tumor-cell injection, to monitor tumor growth (IMx
Total PSA assay, Abbott Laboratories, Abbott Park, IL). All
animals were sacrificed 8 weeks after tumor-cell injection.
Prior to sacrifice, all mice were radiographed with a Model
MX-20 Laboratory radiography System (Faxitron X-Ray
Corp., Wheeling, IL). Bone mineral density (BMD) was
measured using a PIXImus Lunar densitometer (GE
Healthcare, Waukesha, WI). Tibiae with tumors from 5
animals per group were demineralized and embedded in
paraffin. The remaining 5 tibiae with tumors from each
group were embedded in methacrylate [26,28] for bone
histomorphometrical (BHM) analysis. At sacrifice, serum
was collected for determination of mouse TRACP-5b
activity, using the Mouse TRAP™ Assay, and serum Ca2+
levels, using a PHM 240 pH/ion meter with an ISE25Ca
Ca2+ electrode (Radiometer analytical, Lyon, France).
Bone histomorphometry
Six-micrometer longitudinal sections of undecalcified tib-
iae embedded in methacrylate and stained with Goldner's
stain were used. BHM analysis was performed in the mid-
dle of the tibia, in the area 0.525–1.225 mm below the
growth plate (n = 5 per group, Skeletech, Inc., Bothell,
WA). The percentage of bone volume in tissue volume
(%BV/TV), tumor volume in tissue volume (%TuV/TV),
trabecular thickness in μm (Tb.Th.), trabecular number
per mm (Tb.N.), trabecular separation in μm (Tb.Sp.), the
ratio of osteoblast perimeter to bone perimeter as a ratio
(Ob.Pm./B.Pm.), and the ratio of osteoclast number to
bone surface (N.Oc./BS) were determined. The %BV/TV
and TuV/TV was also measured in the whole longitudinal
section.
Immunohistochemistry
Antigen retrieval was performed on 5 μm paraffin sections
of tumored tibiae in 10 mM citrate buffer (pH 6) for 20
min at 120°C in an autoclave. The slides were then incu-
bated with 3% H2O2 for 10 min to block endogenous per-
oxidase activity, with avidin/biotin blocking solution
(Vector Laboratories Inc. Burlingame, CA) for 30 min, and
finally with a 5% chicken/goat/horse serum solution for 1
h at room temperature. The tissue was stained with a rab-
bit polyclonal anti-human RANKL antibody (AB1862, 1/
1000 dilution, Chemicon International, Temecula, CA)
for 1 h at room temperature. Control slides were incu-
bated with rabbit IgG under the same conditions as the
primary antibody. All slides were then incubated with a
biotinylated goat anti-rabbit secondary antibody (1:150,
Vector Laboratories Inc.) for 30 min at room temperature,
and immunoreactivity was detected using the Vectastain
ABC kit (Vector Laboratories Inc.) and stable DAB (Invit-
rogen Corp.).
Data analyses
Statistical analyses of the results were performed using
Prism software (Prism Graphpad, San Diego, CA). Signif-
icance of differences was evaluated using paired and
unpaired Student's t tests as appropriate, with p values ≤
0.05 indicating statistical significance.
Results
Determination of the specificity of huRANKL MAb
Effects of huRANKL MAb on human RANKL-induced Ca2+ release in 
mice
In our first experiments, we used normal non-tumor-bear-
ing wild-type mice to establish that the anti-huRANKL
MAb effectively inhibits human RANKL-induced increases
in serum ionized Ca2+ levels in vivo, without showing evi-
dence for the inhibition of murine RANKL. Administra-
tion of human RANKL to mice increased serum Ca2+
levels. huRANKL MAb inhibited these effects in a concen-
tration-dependent manner. Administration of high doses
of huRANKL MAb (10 mg/kg) completely inhibited Ca2+
release stimulated by human RANKL, returning Ca2+ lev-
els to control levels. OPG-Fc used as a positive control for
inhibition of RANKL-induced osteolysis also inhibited
Ca2+ release, reducing Ca2+ levels beyond control levels
(Figure 1A).
Effects of OPG-Fc and huRANKL MAb on systemic TRACP-5b activity 
in mice
The administration of OPG-Fc to mice significantly
decreased systemic TRACP-5b activity in serum of treated
mice (p < 0.0001). However, huRANKL MAb treatment
was unable to inhibit TRACP-5b activity in the serum of
mice (p = 0.1769) (Figure 1B). After obtaining data that
huRANKL MAb inhibits human RANKL, but not mouse
RANKL activity in vivo, we set out to examine the effects ofBMC Cancer 2007, 7:148 http://www.biomedcentral.com/1471-2407/7/148
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huRANKL MAb on osteolysis associated with the growth
of C4-2 in the bone environment.
Effects of huRANKL MAb on experimental CaP bone 
metastases
Once we had established the anti-human RANKL specifi-
city of the huRANKL MAb, we used the C4-2 tibial injec-
tion model of experimental bone metastases in SCID mice
in combination with the huRANKL MAb to test our
hypothesis. All animals had tumor cells growing in the
tibiae, as demonstrated by serum PSA levels that were
detectable at week 2 after tumor-cell injection and
increased thereafter. Expression of RANKL in C4-2 tumors
in tibiae was confirmed by immunohistochemistry (Fig-
ure 2A). Administration of huRANKL MAb did not signif-
icantly alter establishment or growth of tumors in the
bone as represented by serum levels of PSA (Figure 2B)
and the final tumor volume (Table 1).
Radiography of the tibiae was used to assess the impact of
the C4-2 tumors on the integrity of the bone (Figure 3A).
In the site of injection adjacent to the growth plate, the
cortical shaft was eroded and C4-2 tumor cells had
replaced the marrow and both the trabecular bone and
cortical shaft had been degraded in all groups. In some
cases tumor was present outside the cortical shaft (Figure
3A); no significant differences in bone destruction were
observed between animals from either groups (Table 1).
The destruction of bone associated with the growth of C4-
2 cells in the tibiae was demonstrated by decreases in
BMD, similarly to our previous data [18,27]; however,
administration of huRANKL MAb did not have any signif-
icant effects on BMD of tumored or contralateral tibiae
(Figure 3B).
Histomorphometrical analyses showed that huRANKL
MAb did not alter bone volume (control vs. prevention: p
= 0.5146; control vs. treatment: p = 0.6467) or tumor vol-
ume (control vs. prevention: p = 0.5920; control vs. treat-
ment: p = 0.5232) both measured in the region next to the
growth plate. Other measurements included trabecular
thickness (control vs. prevention: p = 0.6182; control vs.
treatment:  p  = 0.6140), trabecular number (control vs.
prevention: p = 0.9855; control vs. treatment: p = 0.7119)
or trabecular separation (control vs.  prevention:  p  =
0.8950; control vs. treatment: p = 0.9188). A significant
increase in the ratio of osteoblast perimeter to bone
perimeter between control vs.  prevention (p  = 0.0227)
and osteoclast number to bone surface between control vs.
treatment (p = 0.0238) was detected (Table 1). Since the
differences in the ratio of osteoclast number to bone sur-
face were detected only between the control and treatment
groups, but not control vs prevention groups, we speculate
that these differences might be associated with the anar-
chic nature of the bone response to the C4-2 cells and may
not be biologically relevant.
A: Measurement of serum calcium levels in OPG-Fc- and  huRANKL MAb-treated mice challenged with human RANKL Figure 1
A: Measurement of serum calcium levels in OPG-Fc- and 
huRANKL MAb-treated mice challenged with human 
RANKL. Young male BDF1 mice (4–5 weeks old) were chal-
lenged twice daily (by SC injection, morning and evening) 
with either PBS (closed squares) or with human RANKL (0.5 
mg/kg, closed diamonds) for 6 days. Immediately prior to the 
first human RANKL challenge, mice were given a single SC 
injection of either PBS or OPG-Fc (3 mg/kg; open triangle), 
or huRANKL MAb (1, 3, or 10 mg/kg). Results are expressed 
as mean ± SE. B: Systemic levels of TRACP-5b in sera of mice 
challenged with OPG-Fc and huRANKL MAb. 12-week-old 
female BALB/c mice (n = 5 per group) were given a single 
subcutaneous injection of PBS, (Vehicle), OPG-Fc (10 mg/kg), 
or huRANKL MAb (10 mg/kg). TRACP-5b concentration was 
detected in sera one hour before (baseline) and 72 h after 
treatment (Mouse TRAP Assay, SBA Sciences). TRACP-5b 
concentration was significantly different between Vehicle and 
OPG-Fc treated animals (p < 0.0001). TRACP-5b concentra-
tion was not significantly different between Vehicle and 
huRANKL MAb treated animals (p = 0.1769). Results are 
expressed as mean ± SE.BMC Cancer 2007, 7:148 http://www.biomedcentral.com/1471-2407/7/148
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To further evaluate the effects of huRANKL MAb on C4-2-
induced osteolysis we measured levels of mouse serum
TRACP-5b enzymatic activity. No significant differences
in TRACP-5b activity were detected between the groups
(Figure 4A). In contrast there were significant differences
in serum Ca2+ concentrations between control and pre-
vention (p = 0.012), and prevention and treatment (p =
0.0225), while no differences were detected between con-
trol and treatment groups (Figure 4B).
Discussion
Even in patients with osteoblastic bone metastases, an
osteolytic reaction is also frequently present; however the
mechanisms of stimulation of this osteolytic reaction
have not been fully elucidated. It has been reported by us
and others that CaP cells express RANKL mRNA and pro-
tein [14-16,29-33]. Moreover, we have shown that CaP
cells in the bone environment express higher levels of
RANKL than in primary tumors or soft-tissue metastases
[14], and Zhang et al. demonstrated activation of tran-
scription of RANKL in C4-2B cells in the tibiae of mice
[34]. The critical role of RANKL/RANK signaling in CaP
associated osteolysis has been demonstrated by studies
showing that the inhibition of RANKL/RANK signaling
decreases tumor associated osteolysis which subsequently
results in decreased CaP growth in the bone environment
[16,18,20,35]. We have shown previously that adminis-
tration of OPG or over-expression of OPG inhibits the
osteolytic response of the bone to C4-2 cells in vivo, clearly
demonstrating a critical role for RANKL in this process
[18,21]. Similar results were reported in breast cancer and
myeloma bone metastases [23,36-38]. In our present
study we set out to investigate whether RANKL expressed
by human CaP cells in the murine bone environment is
involved in direct stimulation of osteoclastogenesis and
osteoclast activity or whether the increases in osteolysis
are associated with the ability of the tumor cells to elabo-
rate factors that induce host production of RANKL.
In patients RANKL is expressed by both osteoblasts and
CaP cells, and it is impossible at present to distinguish the
relative contributions of each cell type to the osteolytic
component of bone metastases. In the C4-2 tibial injec-
tion model of experimental bone metastases, the tumor
cells express human RANKL, while the osteoblasts express
murine RANKL. The use of a xenograft model and a spe-
cies-specific RANKL inhibitor provides an elegant model
to discern the relative contributions of RANKL derived
from tumor cells versus other cell types in the bone micro-
environment. This is not possible when using molecules
such as OPG-Fc, or soluble RANK-Fc, which each inhibit
the action of both mouse and human RANKL. The use of
a neutralizing muRANKL MAb might be an alterative way
to test this hypothesis; however, we are not aware of an
antibody that would specifically recognize murine RANKL
and possess neutralizing capabilities.
In our experimental model of CaP growth in the bone,
administration of the anti-huRANKL MAb did not signifi-
cantly inhibit osteolysis associated with the growth of C4-
2 cells in the bone, suggesting that the RANKL expressed
by these tumor cells is not the driving force for tumor-
associated osteolysis in this model. We hypothesize that
the interactions between tumor cells and cells within the
bone results in increased expression of RANKL on osteob-
lasts. In support of our hypothesis it has also been
reported that DU 145 cells produce soluble factor(s),
which increased local RANKL expression and activated
both osteoclasts/osteoclast precursors [39]. Other groups
A: Immunohistochemical analysis of RANKL in C4-2 tumored tib- iae of control, prevention, and treatment groups Figure 2
A: Immunohistochemical analysis of RANKL in C4-2 tumored tib-
iae of control, prevention, and treatment groups. Paraffin-embed-
ded C4-2 tumored tibiae of the SCID mice were sectioned and 
stained for RANKL (negative control staining is shown in inset 
box). The tumor cells stained positively for RANKL. B: Blood was 
collected to determine serum PSA levels by IMx Total PSA assay. 
Serum PSA levels were not significantly different between the C4-
2 control with PBS injections (control), C4-2 with a concomitant 
subcutaneous injection of huRANKL MAb (5 mg/kg once a week) 
at implantation (prevention group), or C4-2 with a subcutaneous 
injection of huRANKL MAb (5 mg/kg biweekly, starting 3 weeks 
after implantation of C4-2 cells) (treatment group). Results are 
presented as mean ± SE.BMC Cancer 2007, 7:148 http://www.biomedcentral.com/1471-2407/7/148
Page 6 of 9
(page number not for citation purposes)
have also determined that osteoblasts can upregulate oste-
oclastogenesis associated factors in response to breast and
prostate cancer cells in vitro [40,41]. Furthermore, breast
cancer cells altered the phenotype of osteoblast cells, caus-
ing increased expression of various osteoclast stimulating
factors [42]. Potential candidate factors are IL-11 and oste-
opontin, which were shown to stimulate recruitment and
activation of osteoclasts in breast cancer osteolytic metas-
tases, and IL-7 that can stimulate spontaneous osteoclas-
togenesis in bone metastases [43,44]. Both of these
proteins are also secreted by CaP cells [45,46]. IL-11 is an
interesting candidate gene, as IL-11 has been shown to
increase RANKL expression in bone, and OPG fully pre-
vented IL-11 induced bone resorption [47].
Another anti-human RANKL neutralizing antibody,
AMG162 (denosumab, Amgen, Inc.), is a potent anti-
resorptive agent that is currently under clinical evaluation
as a treatment for cancer-induced bone loss and other
bone-loss disorders [48-50]. In patients, the tumor cells
and osteoblasts express human RANKL and therefore
denosumab will inhibit the actions of RANKL expressed
by both cell types. In addition, the use of denosumab has
potential advantages as a therapeutic agent over other
RANKL inhibitors, such as OPG, because denosumab
does not bind to TRAIL and it also has a longer half-life in
vivo compared to OPG [51-53].
We detected significant decreases in serum levels of Ca2+
in the tumored animals associated with long-term admin-
istration of the anti-huRANKL MAb. This effect has not
been observed in previous studies (our unpublished
data). Since no other alteration consistent with effects on
osteoclast number or activity was observed, we hypothe-
size that long-term administration of the anti-huRANKL
MAb might exhibit weak effects on osteoclastogenesis
caused by mouse RANKL or that administration of
huRANKL MAb inhibits human RANKL/RANK signaling
in the CaP cells, altering expression of other factors
secreted by these cells that are involved in decreasing
serum Ca2+ levels.
Table 1: Effect of huRANKL treatment of C4-2 cells on bone morphometry
BV/TV (%) TuV/TV (%) Tb.Th. (μm) Tb.N. (mm-1) Tb.Sp. (μm) Ob.Pm./B.Pm. (%) N.Oc./BS (#/mm)
Control 5.88 ± 0.99 80.48 ± 2.49 31.58 ± 4.83 2.03 ± 0.42 597.24 ± 215.70 5.23 ± 1.03 4.06 ± 0.37
Prevention 6.65 ± 2.31 78.69 ± 2.06 34.27 ± 2.05 1.84 ± 0.50 690.77 ± 188.80 9.51 ± 1.76a 4.37 ± 0.71
Treatment 6.75 ± 1.72 77.85 ± 2.99 36.00 ± 4.80 1.79 ± 0.37 633.46 ± 193.00 8.35 ± 2.66 6.32 ± 0.50b
Bone histomorphometric analysis was performed in the area adjacent to the growth plate (0.525–1.225 mm below the growth plate: site of injection, n = 4 in control and 
treatment animals; n = 5 in prevention animals. Two animals were removed from the analysis due to sectioning difficulties. Results are expressed as mean ± SE. Statistical 
significance was evaluated using student's paired t test. a Control vs. prevention (p < 0.05). b Control vs. treatment (p < 0.05). Abbreviations: %BV/TV, percentage bone volume 
in tissue volume; %TuV/TV, tumor volume in tissue volume as a percentage; Tb.Th., trabecular thickness in μm; Tb.N., trabecular number per mm; Tb.Sp., trabecular 
seperation in μm; Ob.Pm./B.Pm., osteoblast perimeter to bone perimeter; N.Oc./BS, ratio of osteoclast number to bone surface.
A: Characteristics of C4-2 tumor-bearing tibiae Figure 3
A: Characteristics of C4-2 tumor-bearing tibiae. Upper panel: radi-
ographs of the right and left tibiae of representative animals from 
control, prevention, and treatment groups. Arrows indicate areas of 
the eroded cortical shaft in tumored tibiae of C4-2-treated animals. 
Middle panel: mineralized tibiae were harvested 8 weeks after 
tumor injection and embedded in methacrylate and 6 μm sections 
were stained with Goldner's stain. In tumor-bearing animals the 
tumor replaced the marrow, filling the cavity and degrading the 
trabecular bone. Arrows indicate areas of the eroded cortical shaft 
where the tumor has started to extravasate. B: Bone mineral density 
(BMD) was measured 8 weeks after intra-tibial C4-2 injection in 
SCID mice. There was no significant difference in BMD between con-
trol and prevention (p = 0.1491) or control and treatment (p = 
0.8601) animals. Results are presented as mean ± SE.BMC Cancer 2007, 7:148 http://www.biomedcentral.com/1471-2407/7/148
Page 7 of 9
(page number not for citation purposes)
As discussed above, we observed no increases in serum
Ca2+ levels in animals treated with the anti-huRANKL
MAb compared to untreated tumored animals. Nor did
we observe increases in TRACP 5b activity after anti-
huRANKL MAb administration. As the bone destruction
and osteoclastic activity was localized to the right tibia
and not systemic, our assays may not have been able to
detect minor changes in TRACP 5b activity or serum Ca2+
levels. These assays do suggest, however, that the anti-
huRANKL antibody did not have a systemic effect on
murine RANKL as osteoclast activity and serum Ca2+ levels
did not alter between tumored animals and animals
treated with anti-huRANKL MAb. This is a further indica-
tion that the antibody anti-huRANKL MAb does not inter-
act with murine RANKL.
We are cognizant that these studies have certain limita-
tions and are subject to alternative interpretations. For
example, it could be argued that the dose of the anti-
huRANKL MAb (5 mg/kg) resulted in insufficient levels of
the MAb in the tumor-bone microenvironment to inhibit
huRANKL-mediated osteolysis. However, we do not
believe that low levels of the huRANKL MAb are responsi-
ble for absence of an effect on osteoclast numbers, since a
lower dose of huRANKL MAb (3 mg/kg) inhibited the
action of high-dose human RANKL (0.5 mg/kg) in the cir-
culation for four days. It is also possible that the inhibi-
tion kinetics of membrane bound and soluble RANKL are
different. Prostate tumor cells were shown to produce
membrane-bound as well as soluble RANKL [16], but the
proportion of these forms in vivo has not been deter-
mined.
We attempted, but were unable, to demonstrate immuno-
reactivity of the huRANKL MAb on the C4-2 cells in the
bone microenvironment of the tumor-bearing treated ani-
mals (data not shown). Not all antibodies recognize the
targeted protein after formalin fixation and embedding in
paraffin. Therefore the lack of immunoreactivity does not
necessarily mean the absence of the target protein. In this
particular case, because we have shown expression of
RANKL in C4-2 cells in the tibiae using other antibodies,
as well as RANKL expression in cells grown in vitro, we
have concluded that the lack of immunoreactivity of
RANKL under immunohistochemical conditions with the
huRANKL MAb is due to its inability to recognize the pro-
tein in paraffin-embedded tissues. We believe that our
selection of this model for our studies is justified for fol-
lowing reasons: 1) we have shown previously that their
growth in the bone results in increases in bone destruc-
tion; 2) these cells express RANKL; and 3) RANKL is
involved in this process.
In this study, administration of huRANKL MAb did not
inhibit growth of C4-2 cells within the bone. Since admin-
istration of this antibody did not inhibit osteolysis, our
results are consistent with the literature showing that inhi-
bition of RANKL/RANK signaling by OPG does not
inhibit the proliferation of tumor cells injected subcutane-
ously in mice [16]. Together these results support the
hypothesis that the inhibition of tumor growth by OPG in
the bone environment is due to the indirect effects of
OPG, through the inhibition of osteolysis and the direct
inhibition of RANK/RANKL signaling in tumor cells.
A: The tartrate-resistant acid phosphatase assay was per- formed according to the manufacturer's instructions on  mouse serum samples from control, prevention, and treat- ment groups, using the Mouse TRAP™ Assay measuring  TRACP-5b activity (Immunodiagnostic systems Inc.) (n = 10) Figure 4
A: The tartrate-resistant acid phosphatase assay was per-
formed according to the manufacturer's instructions on 
mouse serum samples from control, prevention, and treat-
ment groups, using the Mouse TRAP™ Assay measuring 
TRACP-5b activity (Immunodiagnostic systems Inc.) (n = 10). 
There were no significant differences associated with 
huRANKL MAb administration. B: Serum calcium levels were 
measured using a calcium ion electrode 8 weeks after intra-
tibial C4-2 injection in the control, prevention, and treat-
ment groups. Serum calcium levels were significantly different 
between control and prevention animals (p = 0.012). Serum 
calcium levels were not significantly different between con-
trol and treatment animals (p = 0.9631).BMC Cancer 2007, 7:148 http://www.biomedcentral.com/1471-2407/7/148
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However, RANKL signaling has been shown to be impor-
tant for metastatic spread of tumor cells [54]. These effects
were not amenable to study by the methods reported
herein, since we injected tumor cells directly into the bone
and therefore could not investigate release and trafficking
of tumor cells or seeding of tumor cells at secondary sites.
Conclusion
In conclusion, while RANKL is expressed by CaP cells, and
the anti-huRANKL MAb can effectively block activity of
human RANKL, our data suggest that tumor-derived
RANKL may not be a central player in promoting osteoly-
sis in this model. Our current model supports the notion
that C4-2 cells express a factor/s other than RANKL that
are ultimately responsible for recruitment and activation
of osteoclasts. Based on the ability of OPG to prevent oste-
olysis and reduce CaP tumor burden in bone, we hypoth-
esize that CaP-derived factor(s) induce the production of
RANKL within bone, which then culminates in local oste-
olysis and the stimulation of tumor growth. Our results
warrant further studies to identify factors upstream of
RANKL that may be involved in stimulating the osteolytic
component observed in this model.
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